ArticleCurrent microbiology2025
Emergence of MDR Enterobacter hormaechei RSM5 in Pharma Effluent and its Implications in β-lactam Antibiotic Removal from Effluent.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance poses the biggest threats to global health and development and also to food security. β-lactam antibiotics (BLAs) responsible for the transpeptidation/cross-linking process during cell wall biosynthesis contribute to the maximum resistance. The production of β-lactamase enzyme is a significant contributing factor to the development of antibiotic resistance to β-lactam antibiotics. Unintentional disposal of antibiotics from the manufacturing units of pharma industries to the water bodies enhances the exposure of antibiotics, contributing to resistance. This study describes the presence of > 50 antibiotic-resistant bacterial strains in pharma effluent of Himachal Pradesh, India. Among 54 isolates, 40% showed ampicillin resistance above 100 µg/mL, 13% showed resistance above 5000 µg/mL, and 3 strains showed resistance at 15,000 µg/mL of ampicillin. Enterobacter hormaechei RSM5 showed the highest minimum inhibitory concentration (MIC) and cell viability and was selected for further studies. It produces lactamase (0.24 U/mL) to resist the higher concentration of antibiotics present in the media/effluent and demonstrated resistance against 3 different classes of antibiotics, confirming its status as a multidrug resistance (MDR) strain. The high-performance liquid chromatography (HPLC) analysis of the isolate demonstrated that Enterobacter hormaechei RSM5 can degrade ampicillin within 24 h of incubation in medium/effluent. The emergence of Enterobacter as a pathogen with antibiotic resistance poses a significant health concern that could also be explored for the removal of antibiotics from the effluent at the source. The future of research in this area needs to be open and mindful of new approaches.
Indexed as
Identifiers
39920455What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.